<DOC>
	<DOCNO>NCT01195311</DOCNO>
	<brief_summary>This open label , dose escalation study use 3 + 3 design determine INCB024360 ( study drug ) safe , well-tolerated effective patient advanced malignancy . Patients enrol treated cohort three observe minimum 28 day next group enrol may begin receive study drug . For subject safety , first subject cohort administer drug one week next two subject cohort begin drug administration . Doses escalated unless dose-limiting toxicity ( DLT ) observe one three subject . An expanded cohort 15 patient may recruit explore safety 'maximum tolerate dose ' low , pharmacologically active , dose .</brief_summary>
	<brief_title>A Dose-escalation Study Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Subjects neoplastic disease refractory currently available therapy effective treatment available Subjects life expectancy 12 week longer . Subjects Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Subjects receive anticancer medication 21 day prior receive first dose study medication 6 week mitomycinC nitrosoureas . Subjects history brain metastasis spinal cord compression . Subjects undergone bone marrow solid organ transplant . Subjects major surgery within 4 week prior study entry minor surgical procedure within 7 day prior initiate treatment . Subjects history gastrointestinal condition Is receive compound know potent inducer inhibitor CYP3A4 Subjects active autoimmune process receive therapy autoimmune disease Subjects treat serotonin reuptake inhibitor within 3 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Refractory , Advanced malignancy</keyword>
</DOC>